Natera Inc (NASDAQ:NTRA) COO Steven Leonard Chapman sold 562 shares of the firm’s stock in a transaction dated Monday, September 24th. The shares were sold at an average price of $23.78, for a total value of $13,364.36. Following the completion of the sale, the chief operating officer now owns 4,324 shares of the company’s stock, valued at $102,824.72. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Steven Leonard Chapman also recently made the following trade(s):
- On Wednesday, September 19th, Steven Leonard Chapman sold 35,000 shares of Natera stock. The shares were sold at an average price of $23.81, for a total value of $833,350.00.
- On Tuesday, September 11th, Steven Leonard Chapman sold 45,000 shares of Natera stock. The shares were sold at an average price of $25.16, for a total value of $1,132,200.00.
NTRA stock opened at $24.78 on Thursday. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of -10.33 and a beta of 2.21. The company has a debt-to-equity ratio of -3.32, a current ratio of 1.69 and a quick ratio of 1.56. Natera Inc has a 52-week low of $8.60 and a 52-week high of $29.62.
Natera (NASDAQ:NTRA) last released its quarterly earnings results on Wednesday, August 8th. The medical research company reported ($0.55) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.55). The business had revenue of $63.07 million during the quarter, compared to the consensus estimate of $61.71 million. Natera had a negative return on equity of 752.93% and a negative net margin of 59.07%. The company’s quarterly revenue was up 20.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.55) EPS. analysts forecast that Natera Inc will post -2.05 EPS for the current year.
A number of hedge funds have recently added to or reduced their stakes in the business. Northern Trust Corp boosted its stake in Natera by 1.5% during the 1st quarter. Northern Trust Corp now owns 375,674 shares of the medical research company’s stock valued at $3,483,000 after purchasing an additional 5,428 shares during the last quarter. Swiss National Bank lifted its position in shares of Natera by 13.2% during the 1st quarter. Swiss National Bank now owns 47,900 shares of the medical research company’s stock worth $444,000 after buying an additional 5,600 shares in the last quarter. State of Wisconsin Investment Board lifted its position in shares of Natera by 30.4% during the 2nd quarter. State of Wisconsin Investment Board now owns 30,000 shares of the medical research company’s stock worth $565,000 after buying an additional 7,000 shares in the last quarter. Trexquant Investment LP lifted its position in shares of Natera by 76.6% during the 2nd quarter. Trexquant Investment LP now owns 22,643 shares of the medical research company’s stock worth $426,000 after buying an additional 9,820 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System bought a new position in shares of Natera during the 2nd quarter worth approximately $200,000. Institutional investors and hedge funds own 66.31% of the company’s stock.
NTRA has been the subject of several research reports. Morgan Stanley raised their target price on Natera from $16.00 to $20.00 and gave the company an “overweight” rating in a research note on Monday, June 25th. Piper Jaffray Companies raised their target price on Natera to $27.00 and gave the company an “overweight” rating in a research note on Thursday, August 9th. Robert W. Baird lifted their price target on Natera from $17.00 to $20.00 and gave the company an “outperform” rating in a research note on Thursday, June 28th. ValuEngine upgraded Natera from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 22nd. Finally, Craig Hallum set a $23.00 price target on Natera and gave the company a “positive” rating in a research note on Thursday, June 28th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Natera presently has a consensus rating of “Buy” and a consensus price target of $23.14.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Article: NASDAQ
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.